TME Pharma announces further improvement in median overall survival at 19 months follow-up in GLORIA brain cancer trial
. Median overall survival surpasses 19 months and continues to improve in glioblastoma patients receiving NOX-A12 combination with radiotherapy and bevacizumab Survival rate in this cohort at 19 months is 10-fold greater than a reference cohort of matched patients receiving Mehr




